EU Agencies Update
The management board has a supervisory role with general responsibility for budgetary and planning matters, the appointment of the Executive Director, and the monitoring of the Agency's performance.
EMEA Board
The management board has a supervisory role with general responsibility for budgetary and planning matters, the appointment of the Executive Director, and the monitoring of the Agency's performance.
European Commission
Heinz Zourek +32 2 299 80 01
Georgette Lalis +32 2 298 79 30
Isabel de la Mata +352 4301 33988
Bernard Merkel +32 2 299 21 00
European Parliament
Giuseppe Nisticò +9 36 63532608
Björn Lemmer +49 621 3839704
bjoern.lemmer@pharmtox.uni-heidelberg.de
Jozef Holomá +421 2 59369505
Austria
Marcus Müllner, +43 50 55536000
Christian Kalcher +43 1 711 00 48 94
Belgium
Xavier De Cuyper +32 2 5248400
André Lhoir +32 2 524 8080
Bulgaria
Elena Masseva +359 2 8903494
Cyprus
Panayiota Kokkinou +357 22 40 71 03
George Antoniou +357 22 407112
Czech Republic
Lenka Balážová +42 272 185203
Jiří Bureš +420 541 518275
Denmark
Jytte Lyngvig +45 44 88 95 55
Paul Schüder +45 33 92 32 24
Estonia
Kristin Raudsepp +372 7 37 41 40
kristin.raudsepp@ravimiamet.ee
Alar Irs +372 7 374 140
Finland
Pekka Järvinen +358 9 16 07 38 00
France
Marc Mortureux +33 1 49771350
Jean Marimbert +33 1 55 87 30 14
jean.marimbert@afssaps.sante.fr
Germany
Walter Schwerdtfeger +49 1888 441 1100
walter.schwerdtfeger@bmg.bund.de
Hans-Peter Hofmann +49 228 4411120
hans-peter.hofmann@bmg.bund.de
Greece
Dimitra Patargia +30 210 6507204
Hungary
Tamás L. Paál +36 1 88 69 320
Beatrix Horváth +36 1886 9320
Iceland
Ingolf J. Petersen +354 545 87 00
Rannveig Gunnarsdòttir +354 520 2100
rannveig.gunnarsdottir@imca.is
Ireland
Pat O'Mahony (chair) +353 1 634 34 53
Rita Purcell +353 1 634 3438
Italy
Guido Rasi +39 06 59784205
Silvia Fabiani +39 06 59 78 43 17
Latvia
Inguna Adovica +371 670 784 31
Dace Kikute +37 1 67078411
Liechtenstein
Brigitte Batliner +423 236 7325
Sabine Erne
Lithuania
Mindaugas Buta +370 5 212 4059
Jonas Milius +370 5 2780470
Luxembourg
Mariette Backes-Lies +352 478 55 90
mariette.backes-lies@ms.etat.lu
Claude Hemmer +352 478 55 20
Malta
Patricia Vella Bonanno +356 23 43 90 00
The Netherlands
Aginus A.W. Kalis +31 70 3567450
Rob De Haan
Norway
G. Ramsten Wesenberg +47 22 897700
gro.wesenberg@legemiddelverket.no
Hans Halse +47 22 897705
Poland
Wojciech Matusewicz +48 22 5667200
Jacek Splawinski +48 22 841 04 10
Portugal
A.J. Maria Rui Vasco +351 21 798 71 09
F. Manuel d'Almeida +351 21 3239654
subdirgeral@dgv.min-agricultura.pt
Romania
Daniel Boda +40 21 3171102
Slovakia
Jan Mazag +421 2 50701 119
Dagmar Stará +421 2 50 70 12 51
Slovenia
Martina Cvelbar +386 8 2000508
Vesna Koblar +386 8 2000502
Spain
C. Avendaño-Solà +34 91 8225028
L. Franqueza García+34 91 8225040
Sweden
Christina Åkerman +46 18 174600
Johan Lindberg +46 8 4052077
johan.lindberg@social.ministry.se
United Kingdom
Kent Wood +44 20 70842546
Steve Dean +44 1932 338301
Patient organizations
Mike O'Donovan +44 (0)1344 623680
M.G. Baker +44 1483 763626
Doctors
Lisette Tiddens-Engwirda +32 2 732 72 02
Information current as of 11/09
Emails available in online edition
FDA to Launch National Priority Voucher Program to Speed Drug Reviews for Critical Therapies
June 18th 2025Under the new initiative, companies may receive a voucher enabling FDA review to be shortened from the standard 10–12 months to just 1–2 months following final application submission if the drug addresses US national health priorities.
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
May 21st 2025In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.
Phase III SELECT-GCA Trial Results Lead to FDA Approval of Rinvoq for Giant Cell Arteritis
April 30th 2025Rinvoq (upadacitinib) becomes the first oral JAK inhibitor approved by the FDA for the treatment of giant cell arteritis in adults, following robust data from the Phase III SELECT-GCA trial demonstrating its efficacy in achieving sustained remission and reducing glucocorticoid exposure.
